{"id":"alomnertinib-mesilate","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"}]},"_chembl":{"chemblId":"CHEMBL1091841","moleculeType":"Small molecule","molecularWeight":"443.49"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Alomnertinib is designed to selectively target EGFR mutations commonly found in non-small cell lung cancer, particularly the T790M mutation that confers resistance to first and second-generation EGFR inhibitors. By irreversibly binding to the ATP-binding pocket of mutant EGFR, it blocks downstream signaling pathways that drive cancer cell proliferation and survival. This mechanism allows it to overcome resistance mechanisms that develop during treatment with earlier-generation EGFR inhibitors.","oneSentence":"Alomnertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:08:17.862Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations"}]},"trialDetails":[{"nctId":"NCT07229729","phase":"PHASE2","title":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-11-24","conditions":"Non-small Cell Lung Cancer","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1212,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Alomnertinib Mesilate","genericName":"Alomnertinib Mesilate","companyName":"Shanghai Hengrui Pharmaceutical Co., Ltd.","companyId":"shanghai-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alomnertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations. Used for Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}